Organization · Private Equity
NB Capital ApS
NB Capital ApS, founded in 2001 and based in Denmark, focuses on investing in public and private equity markets, primarily in the biopharmaceutical sector. The firm employs principles of risk aversion and innovation to manage approximately $1 billion in discretionary capital.
Overview
What NB Capital ApS does
What NB Capital ApS is
NB Capital ApS, founded in 2001 and based in Denmark, focuses on investing in public and private equity markets, primarily in the biopharmaceutical sector. The firm employs principles of risk aversion and innovation to manage approximately $1 billion in discretionary capital.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Private Equity
- Founded
- Founded in 2001
- Approximate age
- About 25 years
- Structured capabilities
- Funder
- Last reviewed
- March 4, 2026
Official channels
Find NB Capital ApS elsewhere
Open the official website or a supported primary organization account.
Capability profile
NB Capital ApS as a funder
Investment thesis
NB Capital specializes in low-risk investments within the biopharmaceutical sector, aiming for potential upside over a 2-3 year timeframe. The firm employs principles of risk aversion and innovation to navigate complex investment landscapes.
Focus narrative
NB Capital specializes in all phases of pharmaceutical drug development and commercial enterprises. The organization seeks low-risk investments with potential upside over a 2-3 year timeframe, tailored to the risk tolerance of its investors. Its investment strategy is designed to navigate the complexities of the biopharmaceutical sector, which generates annual revenues exceeding one trillion USD globally.
Focus and fit
- Regions
- Europe · Global
Availability
- Currently deploying
- Not published
Portfolio and track record
- Recorded portfolio count
- 6
- Recorded notable exits
- Facet Biotech Corporation and Élan Corporation PLC
Portfolio context
Notable investments by NB Capital include: Genmab A/S: A biotechnology company developing antibody therapeutics for cancer and autoimmune diseases. BioMarin Pharmaceutical Inc.: Focuses on innovative biopharmaceuticals for rare genetic diseases. Facet Biotech Corporation: Engaged in oncology drug development, acquired by Abbott Laboratories. Forward Pharma A/S: Focused on immunomodulatory treatments for immune diseases. ACADIA Pharmaceuticals Inc.: Develops small molecule drugs for central nervous system disorders. Élan Corporation PLC: A former major drug firm focused on neurology and autoimmune diseases, acquired by Perrigo.
Common questions
What to know about NB Capital ApS
Upseed classifies NB Capital ApS under the Private Equity organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 4, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.